



#37315

**DATE:** AUGUST 20, 2015

**SUBJECT:** ADJUSTED TARGACEPT, INC. - FURTHER ADJUSTMENT AND  
NAME/SYMBOL/CUSIP CHANGE  
ADJUSTED OPTION SYMBOL: TRGT1  
NEW SYMBOL: CBIO1  
DATE: 8/21/15

Adjusted Targacept, Inc. (TRGT1) options were adjusted on August 20, 2015. The new deliverable became 1) 100 Targacept, Inc. (TRGT) Common Shares and 2) Approximately \$164.92 Cash (See OCC Information Memo #37293).

On August 18, 2015, Targacept, Inc. (TRGT) shareholders approved a 1-for-7 reverse split and merger with Catalyst Biosciences, Inc. As a result of the reverse stock split and merger, Targacept, Inc. will change its name, trading symbol, and CUSIP to Catalyst Biosciences, Inc. (CBIO), CUSIP 14888D109, and each TRGT Common Share will be converted into the right to receive approximately 0.14285714 (New) CBIO Common Shares. The reverse stock split will become effective before the market open on August 21, 2015.

Adjusted TRGT1 options must be further adjusted to reflect the reverse split and name/symbol/CUSIP change as described below.

### **CONTRACT ADJUSTMENT**

**EFFECTIVE DATE:** August 21, 2015

**OPTION SYMBOL:** TRGT1 changes to CBIO1

**CONTRACT MULTIPLIER:** 1

**STRIKE DIVISOR:** 1

**MULTIPLIER:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 2 yields \$200.00)

**NEW DELIVERABLE PER CONTRACT:**

- 1) 14 (New) Catalyst Biosciences, Inc. (CBIO) Common Shares
- 2) Cash in lieu of approximately 0.285714 fractional CBIO shares
- 3) Approximately \$164.92 Cash

**CUSIP:** CBIO (New): 14888D109

### **PRICING**

Until the cash in lieu amount and final cash amount are determined, the underlying price for CBIO1 will be determined as follows:

$$\text{CBIO1} = 0.14285714 (\text{CBIO}) + 1.6492$$

## **DISCLAIMER**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).